AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Trial: 26584951
Drug: Levodopa/carbidopa 100/25
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Levodopa/carbidopa 100/25 mg TID for 40 weeks (including 2 weeks of dose escalation)
Trial: 26584951
Drug: Levodopa/carbidopa 100/25
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Levodopa/carbidopa 100/25 mg TID for 40 weeks (after initial 40 weeks of treatment)
Trial: 18779882
Drug: Dysport 200
RxNorm normalized name: Dysport
DrugBank: DaxibotulinumtoxinA (DB17929)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Dysport 200 U/ml
Trial: 18779882
Drug: Dysport 150
RxNorm normalized name: Dysport
DrugBank: DaxibotulinumtoxinA (DB17929)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Dysport 150 U/ml
Trial: 18779882
Drug: Dysport 100
RxNorm normalized name: Dysport
DrugBank: DaxibotulinumtoxinA (DB17929)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Dysport 100 U/ml
Trial: 18779882
Drug: Botox 100
RxNorm normalized name: Botox 100 UNT Injection
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Botox 100 U/ml
Trial: 16554494
Drug: Homozygous carriers
RxNorm normalized name: Valiant Barrier
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Homozygous carriers of the G-allele
Trial: 10690944
Drug: Half dose
RxNorm normalized name: propranolol hydrochloride Extended Release Oral Capsule [Half-Betadur CR]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Half dose epinephrine (0.375 microg/min)
Trial: 10690944
Drug: Full dose
RxNorm normalized name: BayRHo-D Full Dose
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Full dose epinephrine (0.75 microg/min)
Trial: 10690944
Drug: Epinephrine studies
RxNorm normalized name: Epinephrine
DrugBank: Epinephrine (DB00668)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Epinephrine studies (both doses)
Trial: 8191053
Drug: Hyperbaric oxygen
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Hyperbaric oxygen therapy with Naftidrofuryl, 1 session per day
Trial: 8191053
Drug: Hyperbaric oxygen
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Hyperbaric oxygen therapy with Naftidrofuryl, 2 sessions per day
Trial: 26027612
Drug: Cyclosporine (2.5
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cyclosporine (2.5 mg/kg intravenous infusion)
Trial: 23215966
Drug: Short treatment
RxNorm normalized name: short ragweed pollen extract Sublingual Tablet [Ragwitek]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Short treatment (three x two-hour sessions)
Trial: 21415156
Drug: Aspirin at
RxNorm normalized name: rose bengal AT
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Aspirin at baseline
Trial: 21415156
Drug: No aspirin
RxNorm normalized name: XS No Aspirin PR
FDA approved: no
EMA approved: no
PMDA approved: no
Description: No aspirin at baseline
Trial: 2524684
Drug: Cyproterone acetate
RxNorm normalized name: cyproterone acetate
DrugBank: Cyproterone acetate (DB04839)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cyproterone acetate 27 mg plus ethinyl estradiol 0.035 mg/day
Trial: 6210867
Drug: Danazol 600
RxNorm normalized name: Danazol
DrugBank: Danazol (DB01406)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Danazol 600 mg/day
Trial: 30957449
Drug: Bupropion hydrochloride
RxNorm normalized name: Bupropion Hydrochloride
DrugBank: Bupropion (DB01156)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Bupropion hydrochloride sustained-release tablets
Trial: 29079252
Drug: Intensive therapy
RxNorm normalized name: Cortaid Intensive Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intensive therapy (HbA1c <6.2% [44.3 mmol/mol], blood pressure <120/75 mm Hg, LDL cholesterol <80 mg/dL [or 70 mg/dL in patients with a history of coronary artery disease])
Trial: 29079252
Drug: Conventional therapy
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Conventional therapy (targets: HbA1c <6.9% [52.0 mmol/mol], blood pressure <130/80 mm Hg, LDL cholesterol <120 mg/dL [or 100 mg/dL in patients with a history of coronary artery disease])
Trial: 23239680
Drug: Milk supplementation
RxNorm normalized name: MILK
DrugBank: Cow milk (DB10543)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Milk supplementation (24 oz/day, one 16-oz dose immediately post-RT)
Trial: 21184185
Drug: Mometasone furoate/formoterol
RxNorm normalized name: mometasone furoate/formoterol fumarate 100/5 MCG/INHAL Metered Dose Inhaler, 60 Actuations
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Mometasone furoate/formoterol fumarate (MF/F) combination
Trial: 17270315
Drug: Eflornithine cream
RxNorm normalized name: eflornithine Topical Cream
DrugBank: Eflornithine (DB06243)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Eflornithine cream plus laser treatment
Trial: 17270315
Drug: Laser treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Laser treatment alone (placebo cream)
Trial: 11699049
Drug: Stress hormone
RxNorm normalized name: Parathyroid Hormone
DrugBank: Parathyroid hormone (DB05829)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Stress hormone infusion
Trial: 3165436
Drug: Levodopa sustained-release
RxNorm normalized name: Levodopa
DrugBank: Levodopa (DB01235)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Levodopa sustained-release (S. R.) formulations
Trial: 3165436
Drug: Standard preparation
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Standard preparation of levodopa
Trial: 28587581
Drug: 40 mg
RxNorm normalized name: rutin 40 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 40 mg enalapril (E) for 4 weeks
Trial: 28587581
Drug: 20 mg
RxNorm normalized name: urea 20 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 20 mg enalapril (E) with or without hydrochlorothiazide (acute treatment)
Trial: 28587581
Drug: 20 mg
RxNorm normalized name: urea 20 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 20 mg enalapril (E) + 16 mg candesartan (EC) for chronic treatment
Trial: 25246074
Drug: HA viscosupplementation
FDA approved: no
EMA approved: no
PMDA approved: no
Description: HA viscosupplementation (3 weekly intra-articular injections of HA)
Trial: 24168767
Drug: Frequent exacerbators
RxNorm normalized name: ethanol
DrugBank: Ethanol (DB00898)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Frequent exacerbators (≥ 2 exacerbations during study treatment)
Trial: 18430744
Drug: Lornoxicam (0.1
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Lornoxicam (0.1 mg kg(‐1))
Trial: 11317154
Drug: Supplemented Group
RxNorm normalized name: Streptococcus viridans group
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Supplemented Group (A) with SUPRO Isolated Soy Protein (1 g/kg body weight)
Trial: 7696152
Drug: CYTOPRESS semi‐automatic
FDA approved: no
EMA approved: no
PMDA approved: no
Description: CYTOPRESS semi‐automatic slide preparation system and CERVIFIP interactive scanner
Trial: 30309755
Drug: Cold tumescence
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cold tumescence anesthesia solution (4°C)
Trial: 30309755
Drug: Room temperature
RxNorm normalized name: ROOM DEODORIZER POWDER MENTOR #3202
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Room temperature tumescence anesthesia solution (24°C)
Trial: 27097858
Drug: Hypnosis prior
RxNorm normalized name: Priorix
DrugBank: Rubella virus vaccine (DB10317)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Hypnosis prior to local anesthesia administration
Trial: 24366425
Drug: High molecular
RxNorm normalized name: dextran, high molecular weight
FDA approved: no
EMA approved: no
PMDA approved: no
Description: High molecular weight (HMW) urinary adiponectin excretion
Trial: 24366425
Drug: HMW-adiponectin excretion
RxNorm normalized name: gonorrheal urethral secretion human
FDA approved: no
EMA approved: no
PMDA approved: no
Description: HMW-adiponectin excretion
Trial: 24366425
Drug: Total adiponectin
RxNorm normalized name: Colgate Total Mouthwash
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Total adiponectin excretion
Trial: 24366425
Drug: Albumin excretion
RxNorm normalized name: Albumin Aggregated
DrugBank: Albumin Aggregated (DB14230)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Albumin excretion rate (AER)
Trial: 22761709
Drug: Diltiazem sustained-release
RxNorm normalized name: diltiazem
DrugBank: Diltiazem (DB00343)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Diltiazem sustained-release capsules (90 mg twice daily)
Trial: 22761709
Drug: Diltiazem sustained-release
RxNorm normalized name: diltiazem
DrugBank: Diltiazem (DB00343)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Diltiazem sustained-release capsules
Trial: 22761709
Drug: Diltiazem sustained-release
RxNorm normalized name: diltiazem
DrugBank: Diltiazem (DB00343)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Diltiazem sustained-release capsules and Placebo
Trial: 7873474
Drug: Low-dose positive
RxNorm normalized name: ethinyl estradiol
DrugBank: Ethinylestradiol (DB00977)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Low-dose positive inotropes (including vesnarinone)
Trial: 25772326
Drug: Bevacizumab plus
RxNorm normalized name: Bevacizumab
DrugBank: Bevacizumab (DB00112)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Bevacizumab plus concurrent oral vinorelbine and capecitabine
Trial: 25772326
Drug: Bevacizumab plus
RxNorm normalized name: Bevacizumab
DrugBank: Bevacizumab (DB00112)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Bevacizumab plus sequential oral vinorelbine and capecitabine
Trial: 23397148
Drug: GLM 100
FDA approved: no
EMA approved: no
PMDA approved: no
Description: GLM 100 mg + MTX
Trial: 23397148
Drug: GLM 50
FDA approved: no
EMA approved: no
PMDA approved: no
Description: GLM 50 mg + MTX
Trial: 23397148
Drug: GLM 50
FDA approved: no
EMA approved: no
PMDA approved: no
Description: GLM 50 mg
Trial: 23397148
Drug: GLM 100
FDA approved: no
EMA approved: no
PMDA approved: no
Description: GLM 100 mg
Trial: 15488964
Drug: 20 mg
RxNorm normalized name: urea 20 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 20 mg ipsapirone orally
Trial: 15488964
Drug: 0.002 mg/kg
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 0.002 mg/kg intravenous clonidine
Trial: 15488964
Drug: Immediate release
RxNorm normalized name: Namenda, immediate release oral kit
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Immediate release venlafaxine (37.5 mg, b.i.d. for low-dose responders; 75 mg, b.i.d. or higher for high-dose responders)
Trial: 10878071
Drug: stavudine-zalcitabine-saquinavir (soft
FDA approved: no
EMA approved: no
PMDA approved: no
Description: stavudine-zalcitabine-saquinavir (soft gel capsule) [d4T-ddC-SQV(SGC)]
Trial: 9145450
Drug: Dietary fibre
RxNorm normalized name: Fiore
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Dietary fibre and lactulose biscuits (11 biscuits containing 10 g dietary fibre, 2 g raw fibre, 8.2 g lactulose)
Trial: 27196764
Drug: FOLFIRI plus
FDA approved: no
EMA approved: no
PMDA approved: no
Description: FOLFIRI plus bevacizumab (first-line treatment)
Trial: 20388497
Drug: Energy-free placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Energy-free placebo solution (PLA)
Trial: 18450787
Drug: Fluoxetine 20
RxNorm normalized name: fluoxetine 20 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Fluoxetine 20 mg daily for 24 weeks
Trial: 8828617
Drug: Low concurrent
RxNorm normalized name: low-density polyethylene
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Low concurrent phenylalanine (Phe) levels
Trial: 8828617
Drug: High concurrent
RxNorm normalized name: high-density polyethylene
FDA approved: no
EMA approved: no
PMDA approved: no
Description: High concurrent phenylalanine (Phe) levels
Trial: 8828617
Drug: Lowering concurrent
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Lowering concurrent phenylalanine (Phe) levels over a period of 4-5 weeks
Trial: 2996905
Drug: Enalapril 20
RxNorm normalized name: enalapril 20 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Enalapril 20 mg once daily (o.d.)
Trial: 2996905
Drug: Enalapril 10
RxNorm normalized name: enalapril 10 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Enalapril 10 mg twice daily (b.d.)
Trial: 28002896
Drug: Hybrid Hyaluronic
RxNorm normalized name: hyaluronate
DrugBank: Hyaluronic acid (DB08818)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Hybrid Hyaluronic Acid (HHA); 3 injections
Trial: 28002896
Drug: Platelet-Rich Plasma
RxNorm normalized name: PLATELET-RICH PLASMA, AUTOLOGOUS
DrugBank: Platelet Rich Plasma (DB19295)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Platelet-Rich Plasma (PRP); 3 injections
Trial: 7870676
Drug: PEG Ointment
RxNorm normalized name: sodium salicylate/peg ointment/butylated hydroxytoluene 2 %-0.2 % TOPICAL OINTMENT (GRAM)
DrugBank: Polyethylene glycol (DB09287)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: PEG Ointment tetracaine
Trial: 3067252
Drug: Combined estrogen‐androgen
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combined estrogen‐androgen preparation
Trial: 2351625
Drug: 750 mg
RxNorm normalized name: bran 750 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 750 mg intravenous dose of cefuroxime
Trial: 2351625
Drug: 500 mg
RxNorm normalized name: bran 500 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 500 mg oral dose of cefuroxime axetil
Trial: 2351625
Drug: AUC0-6 h
FDA approved: no
EMA approved: no
PMDA approved: no
Description: AUC0-6 h after oral dosage
Trial: 2351625
Drug: Abbreviated methods
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Abbreviated methods of assessing bioavailability
Trial: 30790345
Drug: GSK3008356 (DGAT1
FDA approved: no
EMA approved: no
PMDA approved: no
Description: GSK3008356 (DGAT1 inhibitor)
Trial: 23268593
Drug: N-acetylcysteine (NAC)
DrugBank: Acetylcysteine (DB06151)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: N-acetylcysteine (NAC) 300 mg plus 100 mg dimethicone and water up to 100 ml
Trial: 23268593
Drug: Dimethicone 100
RxNorm normalized name: dimethicone 100
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Dimethicone 100 mg (5 ml at 20 mg/ml) plus water up to 100 ml
Trial: 21972619
Drug: Acupuncture therapy
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Acupuncture therapy combined with SSRI (observation group 1)
Trial: 21972619
Drug: Electroacupuncture therapy
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Electroacupuncture therapy combined with SSRI (observation group 2)
Trial: 16507185
Drug: Hyperbaric lidocaine
RxNorm normalized name: Lidocaine
DrugBank: Lidocaine (DB00281)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Hyperbaric lidocaine 20 mg and ropivacaine 5 mg (Group LR)
Trial: 16507185
Drug: Hyperbaric ropivacaine
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Hyperbaric ropivacaine 10 mg (Group R)
Trial: 15573335
Drug: Polyethylene glycol-electrolyte
RxNorm normalized name: Polyethylene Glycol
DrugBank: Polyethylene glycol (DB09287)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Polyethylene glycol-electrolyte solution (PEG-ES)
Trial: 8128430
Drug: Prednisone (P),
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Prednisone (P), 1 mg/kg for 3 weeks, followed by either continued P for an additional 6 weeks, tapering P and beginning cyclophosphamide (C), 2 mg/kg, or continuing P and adding C.
Trial: 8128430
Drug: Cyclophosphamide (C),
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cyclophosphamide (C), 2 mg/kg.
Trial: 8128430
Drug: Combination of
RxNorm normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combination of Prednisone (P) and Cyclophosphamide (C).
Trial: 27552517
Drug: AR-12286 0.5%
FDA approved: no
EMA approved: no
PMDA approved: no
Description: AR-12286 0.5% or 0.7% topical solution, administered once daily for 24 weeks.
Trial: 18925316
Drug: Atorvastatin 20
RxNorm normalized name: atorvastatin 20 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Atorvastatin 20 mg/day for 4 weeks
Trial: 16931936
Drug: TMC278 (25,
FDA approved: no
EMA approved: no
PMDA approved: no
Description: TMC278 (25, 50, 100, or 150 mg once-daily for 7 days)
Trial: 11768837
Drug: Metoclopramide 10
RxNorm normalized name: metoclopramide 10 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Metoclopramide 10 mg every 6 hours for a total of 7 doses
Trial: 11768837
Drug: Cisapride 10
RxNorm normalized name: cisapride 10 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cisapride 10 mg every 6 hours for a total of 7 doses
Trial: 9832953
Drug: Intranasal heroin
RxNorm normalized name: heroin
DrugBank: Diamorphine (DB01452)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intranasal heroin (placebo, 12.5, 25, 50, 100 mg)
Trial: 9832953
Drug: Intranasal heroin
RxNorm normalized name: heroin
DrugBank: Diamorphine (DB01452)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intranasal heroin (100 mg)
Trial: 9832953
Drug: Intranasal heroin
RxNorm normalized name: heroin
DrugBank: Diamorphine (DB01452)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intranasal heroin (various doses)
Trial: 9832953
Drug: Intranasal heroin
RxNorm normalized name: heroin
DrugBank: Diamorphine (DB01452)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intranasal heroin
Trial: 7971646
Drug: Immunosuppressive treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Immunosuppressive treatment (prednisone and azathioprine for 3 months)
Trial: 23761484
Drug: ω‐3 PUFA
FDA approved: no
EMA approved: no
PMDA approved: no
Description: ω‐3 PUFA supplementation (400 mg DHA daily)
Trial: 22279783
Drug: Selzink medicine,
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Selzink medicine, a one-month course of therapy
Trial: 11097668
Drug: 1.2 mL
RxNorm normalized name: Mozobil 24 MG in 1.2 ML Injection
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 1.2 mL (6 mg) of plain 0.5% bupivacaine (group 1; n = 30)
Trial: 11097668
Drug: 1.2 mL
RxNorm normalized name: Mozobil 24 MG in 1.2 ML Injection
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 1.2 mL (6 mg) of hyperbaric 0.5% bupivacaine in 8% glucose (group 2; n = 30)
Trial: 8638546
Drug: Combination chemotherapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combination chemotherapy of 5-fluorouracil (5-FU) and high-dose folinic acid (HDFA)
Trial: 8638546
Drug: Combination chemotherapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combination chemotherapy of 5-FU and HDFA plus low-dose alpha-2b interferon
Trial: 1317694
Drug: Naproxen (loading
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Naproxen (loading dose, 400 mg or 500 mg followed by 200 mg or 500 mg three times daily for 5 days)
Trial: 6543609
Drug: Morphine (2.5
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Morphine (2.5 mg/kg)
Trial: 6543609
Drug: Naloxone (10
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Naloxone (10 mg/kg)
Trial: 10464128
Drug: Azathioprine (40
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Azathioprine (40 mg/kg loading dose followed by 2 mg/kg oral for 16 weeks)
Trial: 9248904
Drug: Intramuscular sumatriptan
RxNorm normalized name: Sumatriptan
DrugBank: Sumatriptan (DB00669)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Intramuscular sumatriptan 6 mg
Trial: 9248904
Drug: Intravenous chlorpromazine,
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intravenous chlorpromazine, 12.5 mg increments to a maximum of 37.5 mg
Trial: 1911008
Drug: Continuous i.m.
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Continuous i.m. infusion of ketorolac 10 mg
Trial: 1911008
Drug: Intermittent i.m.
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intermittent i.m. injection of ketorolac 10 mg administered 4-hourly
Trial: 7139397
Drug: 10 mg
RxNorm normalized name: biotin 10 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 10 mg of succinylcholine (self-taming)
Trial: 7139397
Drug: d-tubocurarine 0.04
FDA approved: no
EMA approved: no
PMDA approved: no
Description: d-tubocurarine 0.04 mg/kg
Trial: 20616673
Drug: 17beta‐E2 (1
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 17beta‐E2 (1 mg/d for 1 mo, then 2 mg/d for 2 mo)
Trial: 16140224
Drug: cetirizine 10mg
RxNorm normalized name: CETIRIZINE 10MG/ML INJ
DrugBank: Cetirizine (DB00341)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: cetirizine 10mg daily
Trial: 6143538
Drug: Betaxolol 5
RxNorm normalized name: betaxolol 5 MG/ML
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Betaxolol 5 mg
Trial: 2573178
Drug: Betaxolol 10
RxNorm normalized name: betaxolol 10 mg oral tablet
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Betaxolol 10 mg
Trial: 6761136
Drug: Betaxolol 40
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Betaxolol 40 mg
Trial: 20845391
Drug: 0.5 mg
RxNorm normalized name: biotin 0.5 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 0.5 mg of melatonin every night for 14 days or until discharge
Trial: 19438696
Drug: Low-dose dobutamine
RxNorm normalized name: ethinyl estradiol
DrugBank: Ethinylestradiol (DB00977)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Low-dose dobutamine
Trial: 19438696
Drug: Infra-low-dose dipyridamole
RxNorm normalized name: Dipyridamole
DrugBank: Dipyridamole (DB00975)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Infra-low-dose dipyridamole
Trial: 9919901
Drug: FUT-175 (40-160
FDA approved: no
EMA approved: no
PMDA approved: no
Description: FUT-175 (40-160 mg/day) administered during the initial 4 days following surgery
Trial: 1976298
Drug: Oral astemizole
RxNorm normalized name: Astemizole
DrugBank: Astemizole (DB00637)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Oral astemizole for 8 weeks
Trial: 31758576
Drug: PF-06480605 1
RxNorm normalized name: PF-05180999
DrugBank: PF-05180999 (DB14885)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: PF-06480605 1 mg, 3 mg, 10 mg, 30 mg, 100 mg, 300 mg, 600 mg, or 800 mg IV (SAD)
Trial: 31758576
Drug: PF-06480605 3
RxNorm normalized name: hypromellose
DrugBank: Hypromellose (DB11075)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: PF-06480605 3 × 500 mg IV, or 3 × 30 mg, 3 × 100 mg, or 3 × 300 mg SC every 2 weeks for three doses (MAD)
Trial: 31156217
Drug: Ampasse (5,
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ampasse (5, 10, or 25 mg intravenously once a day for 15 days)
Trial: 28076709
Drug: 177Lu-Dotatate (7.4
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 177Lu-Dotatate (7.4 GBq every 8 weeks, plus best supportive care including octreotide LAR 30 mg IM)
Trial: 28076709
Drug: Octreotide LAR
RxNorm normalized name: octreotide LAR 20 MG Injection
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Octreotide LAR (60 mg IM every 4 weeks)